TSHA

AI Memo

Taysha Gene Therapies

As of 2026-10-15/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-15 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

REVEAL pivotal six-month interim data • 2027-06-30

Base target: $4 / p=50% prob

Biggest risk

TSHA-102 remains investigational. A small, single-arm pivotal study, uncertain durability, manufacturing qualification and FDA acceptance of the proposed submission path make the 2027 outcome highly binary. Q2 R&D expense rose to $38.6 million from $20.1 million a year earlier. [#SEC-8K-2026-08-11] https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230dex991.htm

Invalidation

Break below $1 or thesis failure.

What would change my mind?

REVEAL dosing is complete, earlier Part A follow-up showed functional gains, and the company reported no severe treatment-related serious adverse events or dose-limiting toxicities among 33 treated patients as of its August cutoff. June-quarter cash of $455.4 million and management's runway estimate into 2H 2028 support the planned readout and BLA work. [#SEC-8K-2026-08-11] https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230dex991.htm

Research note

Recommendation

—

Confidence

medium

As of

2026-10-15

Base target

p=50%

Bull target

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

TSHA-102 manufacturing qualification
FDA feedback on the TSHA-102 BLA pathway
REVEAL dosing is complete, earlier Part A follow-up showed functional gains, and the company reported no severe treatment-related serious adverse events or dose-limiting toxicities among 33 treated patients as of its August cutoff.

BearKey bullets

Higher R&D spending and future commercialization costs could shorten the company's projected cash runway or lead to additional dilution.
[#SEC-8K-2026-08-11]
Longer-term safety and durability, including in younger ASPIRE patients, remain to be demonstrated.

WatchKey bullets

REVEAL pivotal six-month interim data

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $4 (p=50%)

Target spread vs base: +76% / -66%

Scenario probabilities

Bull Target: $7 (p=25%)Base Target: $4 (p=50%)Bear Target: $1 (p=25%)

Commentary

The evidence supports a cautiously positive clinical-development view, not an imminent approval thesis. Taysha's October 1 notice described October 15–17 presentations as encores of previously shared data, not a new readout. https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-multiple-encore-presentations No verified post-release price reaction, current options or short-interest measure, social coverage, or analyst revision series is available; the numeric sentiment fields therefore should not be interpreted as measured neutral readings.

As of 2026-10-15 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

TSHA-102 manufacturing qualification
FDA feedback on the TSHA-102 BLA pathway

Scenarios

Bull Target (Scenario probability)

$7 / p=25% prob

Base Target (Scenario probability)

$4 / p=50% prob

Bear Target (Scenario probability)

$1 / p=25% prob

Analysis 2026-10-15 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-06-30
REVEAL pivotal six-month interim data
The company expects topline results in 1H 2027 after all 17 dosed pivotal-trial patients reach six months of follow-up. The single-arm developmental-milestone response is the central efficacy test; encouraging earlier Phase 1/2 results do not guarantee replication. [#8-K-2026-08-11] [#SEC-8K-2026-08-11] https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230dex991.htm
Prob 65.00% • Move 60.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

TSHA-102 manufacturing qualification
2026-12-31
Taysha expects to complete its BLA-enabling process performance qualification campaign in Q4 2026. Completion would reduce manufacturing execution risk, but would not establish clinical efficacy or FDA approval. [#8-K-2026-08-11] [#SEC-8K-2026-08-11] https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230dex991.htm
Prob 70% • Move 8% • Priced-in 55%

Long-term Catalysts

Months to a year

FDA feedback on the TSHA-102 BLA pathway
2027-06-30
Taysha expects FDA feedback in 1H 2027 on whether the REVEAL interim analysis can support a BLA submission. Its ASPIRE safety study is intended to support a potential label covering patients aged two and older; neither the submission pathway nor label breadth is assured. [#8-K-2026-08-11] [#SEC-8K-2026-08-11] https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230dex991.htm
Prob 55% • Move 30% • Priced-in 35%

Risks

Higher R&D spending and future commercialization costs could shorten the company's projected cash runway or lead to additional dilution. [#SEC-8K-2026-08-11]
Longer-term safety and durability, including in younger ASPIRE patients, remain to be demonstrated. [#SEC-8K-2026-08-11]
Manufacturing qualification, FDA feedback and any broad-label strategy could slip or require additional work. [#SEC-8K-2026-08-11]
REVEAL's 17-patient, single-arm design may not reproduce earlier functional gains or satisfy FDA evidentiary requirements. [#SEC-8K-2026-08-11]

Peers

Symbol	Summary
ACAD	Rett-syndrome commercial comparator, not a gene-therapy development peer: Acadia markets trofinetide. Its product and commercial maturity limit valuation comparability. https://ir.acadia.com/news/news-details/2026/European-Commission-Approves-DAYBU-trofinetide-as-the-First-and-Only-Treatment-for-Neurobehavioral-Symptoms-of-Rett-Syndrome-in-the-European-Union/default.aspx
NGNE	Direct development comparator: Neurogene is advancing NGN-401 gene therapy for Rett syndrome. Trial designs and delivery approaches differ, so its valuation is not a mechanical TSHA multiple. https://ir.neurogene.com/news-releases/news-release-details/neurogene-reports-second-quarter-2026-financial-results-and

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-15

Loading AI feed…

Symbol

Summary

ACAD

Rett-syndrome commercial comparator, not a gene-therapy development peer: Acadia markets trofinetide. Its product and commercial maturity limit valuation comparability. https://ir.acadia.com/news/news-details/2026/European-Commission-Approves-DAYBU-trofinetide-as-the-First-and-Only-Treatment-for-Neurobehavioral-Symptoms-of-Rett-Syndrome-in-the-European-Union/default.aspx

NGNE

Direct development comparator: Neurogene is advancing NGN-401 gene therapy for Rett syndrome. Trial designs and delivery approaches differ, so its valuation is not a mechanical TSHA multiple. https://ir.neurogene.com/news-releases/news-release-details/neurogene-reports-second-quarter-2026-financial-results-and